降钙素基因相关肽类药物治疗偏头痛的研究进展  

Research advances in calcitonin gene-related peptides in treatment of migraine

作　　者：韩卓 (综述) 万东君 马丹丹(审校) HAN Zhuo;WAN Dongjun;MA Dandan(School of Medicine,Northwest Minzu University,Lanzhou 730030,China)

机构地区：[1]西北民族大学医学院,甘肃兰州730030 [2]中国解放军联勤保障部队第九四〇医院神经内科,甘肃兰州730050

出　　处：《中风与神经疾病杂志》2024年第7期604-610,共7页Journal of Apoplexy and Nervous Diseases

基　　金：甘肃省自然科学基金(21JR1RA187)。

摘　　要：偏头痛作为一种全球流行性的原发性头痛,高患病率及失能率对个人及社会造成了严重的负担,应对其进行预防性及急性期治疗。以往的偏头痛治疗策略包括传统镇痛药、曲坦类药物,通常以对症止痛、减少其他伴随症状为主,但长期服用易致药物过量性头痛。近年来,针对降钙素基因相关肽(CGRP)及其受体开发的新药包括单克隆抗体和小分子受体拮抗剂均在偏头痛急性期和预防性治疗中展现了可观的前景,同时可应用于多种药物治疗无效的偏头痛患者。本文将对近年CGRP类药物治疗偏头痛进行综述。Migraine is a common type of primary headache worldwide,and its high morbidity and disability rates have brought heavy burden to individuals and society,thereby requiring preventive and acute treatment.Previous therapeutic strategies for migraine include traditional analgesics and triptans,which are mainly used to relieve pain and reduce accompanying symptoms,but long-term administration of such drugs may lead to medication overuse headache.In recent years,new drugs targeting calcitonin gene-related peptide(CGRP)and its receptors have shown a promising future in the preventive treatment of migraine and the treatment of migraine in the acute stage,such as monoclonal antibodies and smallmolecular receptor antagonists,and in addition,they also can be used in patients who have no response to various pharmacotherapies.This article reviews the recent advances in CGRP drugs in the treatment of migraine.

关 键 词：降钙素基因相关肽 偏头痛 CGRP单克隆抗体 CGRP受体拮抗剂 临床试验 

分 类 号：R747.2[医药卫生—神经病学与精神病学]